

Everest Group Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025

Focus on IQVIA
July 2025



Introduction

Over the past few years, life sciences enterprises have significantly overhauled their R&D investments, driven by streamlined development pipelines and a strategic pivot toward novel and large-molecule therapies. This shift has heightened cost containment imperatives and sparked a growing need for an innovative, tech-enabled approach to commercialization. Concurrently, a rising emphasis on patient-centricity and elevated Customer Experience (CX) expectations has further fueled the outsourcing of commercial operations to specialized service providers.

In response, service providers have emerged as critical enablers of this transformation. By harnessing advanced technologies, such as agentic and generative AI, Machine Learning (ML), and advanced analytics, they are helping enterprises enhance workflow efficiency, reduce time-to-market, and drive strategic impact across the commercialization continuum. Their offerings have matured into comprehensive, end-to-end solutions designed to navigate the intricacies of both pre-launch planning and post-launch execution.

In the report, we present an assessment and the detailed profiles of 30 service providers featured on the report

Life Sciences Al and Analytics Services for Commercial PEAK Matrix® Assessment 2025. Each provider profile provides a comprehensive picture of its service focus, key Intellectual Property (IP) / solutions, domain investments, and case studies. The assessment is based on Everest Group's annual RFI process for the calendar year 2024, interactions with leading life sciences commercial providers, client reference checks, and an ongoing analysis of the life sciences digital services market.

The full report includes the profiles of the following 30 leading life sciences Al and analytics services for commercial providers featured on this assessment:

- Leaders: Accenture, Axtria, Cognizant, Eversana, Indegene, IQVIA, Real Chemistry, Trinity Life Sciences, WNS. and ZS
- Major Contenders: Agilisium, Beghou Consulting, Capgemini, Conexus Solutions, C5i, DataZymes, Fractal Analytics, Genpact, HCLTech, Infosys, MathCo, ProcDNA, Quantiphi, TCS, and Tiger Analytics
- Aspirants: Avira Digital, Customertimes, Everest Customer Solutions, Infocepts, and Quantzig

Scope of this report

Geography: global

Industry: life sciences (biopharmaceutical, medical devices, and others including Contract Research Organizations (CROs))

Services: life sciences commercial

Life Sciences AI and Analytics Services for Commercial PEAK Matrix® characteristics

Leaders

Accenture, Axtria, Cognizant, Eversana, Indegene, IQVIA, Real Chemistry, Trinity Life Sciences, WNS, and ZS

- Leaders offer a full spectrum of solutions across launch strategy, pricing, access, omnichannel marketing, sales enablement, and patient engagement, supported by robust proprietary platforms
- Leaders have operationalized gen Al and agentic Al across commercial use cases, including nextbest-action, marketing mix modelling, and autonomous insight extraction, delivered through copilots and semantic frameworks. This, coupled with deep integration with Salesforce, Veeva, AWS, Microsoft, and Databricks, enables seamless delivery
- Leaders have sustained visibility in the market through frequent publications, conference participation, and client case studies that reinforce domain leadership

Major Contenders

Agilisium, Beghou Consulting, C5i, Capgemini, Conexus Solutions, DataZymes, Fractal Analytics, Genpact, HCLTech, Infosys, MathCo, ProcDNA, Quantiphi, TCS, and Tiger Analytics

- Major Contenders emphasize selected areas, such as field enablement, marketing analytics, content management, or sales forecasting, with deep delivery experience, often supplemented by modular accelerators or proprietary IP
- Many are building gen Al-driven microservices, agent orchestration frameworks, and copilots, typically in pilot or early production stages
- While some have expanded through M&As or ecosystem partnerships, others are expanding into emerging markets such as MedTech or EU/APAC regions, and seeking to transition to a broad commercial solutions partner

Aspirants

Avira Digital, Customertimes, Everest Customer Solutions, Infocepts, and Quantzig

- Aspirants specialize in point solutions such as healthcare professional (HCP) engagement, evidence analytics, or sales operations. Their agile teams, flexible pricing, and personalized service models resonate with small and mid-sized pharma or biotech enterprises
- Gen Al capabilities are generally early-stage and focused on narrow use cases such as summarization. brand research, or sentiment tagging, with limited enterprise-scale deployments
- To scale, Aspirants must build commercial-native IP, expand collaborations with life sciences customer relationship management (CRM) providers, hyperscalers, and niche commercial technology providers, and enhance market visibility through case studies and innovation showcases



Everest Group PEAK Matrix®

Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025 | IQVIA is positioned as a Leader

Everest Group Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 20251

Leaders

Major Contenders

O Aspirants



¹ Assessments for Axtria, Capgemini, Customertimes, Everest Customer Solutions, Eversana, HCLTech, Infocepts, Quantiphi, TCS, and Tiger Analytics exclude provider inputs and are based on Everest Group's proprietary Transaction Intelligence (TI) database, provider public disclosures, and Everest Group's interactions with enterprise buyers

Source: Everest Group (2025)



IQVIA profile (page 1 of 6)

Overview

Company overview

IQVIA is a global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. It connects various aspects of healthcare through its analytics, technology, and extensive expertise. Its IQVIA Connected Intelligence™ offers valuable insights quickly, helping clients speed up clinical development and commercialization of innovative medical treatments that enhance patient outcomes.

Headquarters: Durham, North Carolina Website: www.iqvia.com

Key leaders

- Ari Bousbib, Chairman and CEO
- Ron Bruehlman, EVP and CFO

Suite of commercial services

- Global market insights
- KOL/DOL identification
- Patient analytics
- Information management
- · Launch strategy and management
- Brand strategy and management
- Established brands optimization
- Commercial forecasting
- Omnichannel engagement and insights
- Marketing services

- Bhavik Patel, President, Commercial Solutions
- · Bernd Haas, SVP, Digital Product and Solutions
- Field effectiveness
- Primary intelligence
- Commercial analytics managed services
- Oncology intelligence
- Pricing and market access
- · Contract sales and field medical
- Meeting services
- Patient engagement and support
- Patient experience platform

Life sciences AI and analytics services for commercial revenue (2024) Not disclosed

Recent developments

- 2025: launched new, custom-built AI agents with NVIDIA across a broad range of clinical through commercial use cases, including market assessment and healthcare professional engagement
- 2025: announced collaboration with NVIDIA to develop and optimize AI agents to support precision insights and operational efficiency across numerous key life sciences workflows
- 2024: introduced IQVIA AI Assistant, a generative AI-based technology that significantly enhanced how life sciences customers received timely and powerful insights. The IQVIA AI Assistant featured a user-friendly, conversational text interface that provided immediate and intuitive analytic insights
- 2024: introduced IQVIA Patient Experience Solutions with Apple Devices, the next stage of innovation in patient engagement built on IQVIA Patient Experience Platform
- 2024: partnered with Salesforce to accelerate development of Salesforce's life sciences cloud, a next-gen customer engagement platform built on IQVIA Orchestrated Customer Engagement

Life sciences Al and analytics services for commercial revenue mix (2024)



[NOT EXHAUSTIVE]

IQVIA profile (page 2 of 6)

Technology solutions/tools

Proprietary solutions (representative list)

Solution	Details			
IQVIA Global Market Insights	These syndicated datasets provide a comprehensive view of the pharmaceutical market, encompassing sales, patient volumes, channel spend, message recall, market forecasts, pipeline, and protection insights. IQVIA now offers an agentic AI solution that summarizes, analyzes, and seamlessly connects insights across individual offerings to rapidly deliver centralized, multi-country views that address the needs of many different commercial functions: • IQVIA MIDAS: This data provides global (93 countries) pharmaceutical sale value and volumes and, with >60 years in-market, it is widely recognized as the gold standard in market information. It enables users to measure, segment, and understand market trends to inform business decisions • IQVIA ChannelDynamics: It provides key measures, metrics, and benchmark insights on sales and marketing channel activities of the pharma industry. It combines measured HCP message recall and perception of channel impact and quality to deliver insights on marketing strengths, weaknesses, trends, and performance • IQVIA ChannelDynamics Verbatim: It delivers global and local insights into HCP brand message recall. It offers commercial message profile analysis, competitive comparison, multi-country comparison, channel comparison, and automated translation • IQVIA Market Prognosis: It is a market forecasting publication that provides unparalleled insights into the key issues affecting the local pharmaceutical and healthcare industries to inform strategic planning. Detailed reports are available for 49 countries. The global edition covers 220 countries across 11 regions • IQVIA Analytics Link: It is a business intelligence platform that seamlessly links historical MIDAS data with information from patient, pipeline, trial, launch, protection, and deals, providing customers with an integrated view of their market for 10,000 drugs, 600 diseases, and 76 countries			
IQVIA OneKey Live Access and Accelerated Insights	It is a web-based platform that provides insights from IQVIA OneKey healthcare professional reference data, including medical, clinical, and digital attributes, preferences, and behaviors. These insights support omnichannel marketing campaigns and tailored engagement planning to maximize messaging relevance, resonance, and impact.	2012		
IQVIA Analytics Research Accelerator	It is a platform that provides access to IQVIA's global real-world data assets – including longitudinal patient records, disease-specific cohorts, treatment outcomes, and regulatory-grade datasets – through modular, scalable analytics. It supports cross-functional teams with data identification, data access, cohort development, and cohor analytics for both commercial and real-world use cases. Originally launched as E360, it was rebranded to ARA in 2024.			
IQVIA Launch Strategy and Management (including IQVIA Launch Lighthouse)	agement (including IQVIA and market insights, evidence-based value demonstration and market access, stakeholder engagement, and performance measurement and optimization. IQVIA Laur			

IQVIA profile (page 3 of 6)

Technology solutions/tools

[NOT EXHAUSTIVE]

Proprietary solutions (representative list)

Solution	Details					
IQVIA Dynamic HCP Profiling and Targeting	It is an AI-/ML-based solution designed to identify and segment target healthcare practitioners based on multiple dimensions across populations of interest. This solution leverages a blend of traditional ML techniques or AI-powered models to segment HCPs based on the potential to drive impact.					
IQVIA Patient Characterization and Journey	It is an AI-/ML-based solution designed to map diverse patient profiles, complex patient journeys, and related healthcare provider interactions. This solution provides access to constantly updated analytics to understand competitive share, and diagnosing pathways, eligibility, and prescribing patterns.	2019				
IQVIA Patient Finding and Disease Modeling	It is an AI-/ML-based solution designed to identify and predict opportunity patients specific to market needs. This solution leverages proprietary AI algorithms to analyze over 60 patient and HCP dimensions, delivering up to five times more patients.	2016				
IQVIA Field Alerts (including Integrated Field Alerts)						
Custom-built agentic ai solutions for field engagement	These solutions help field reps efficiently plan for HCP interactions with consolidated, real-time insights from multiple data sources in a flexible, convenient format (conversational interface, audio, etc.), enabling them to prioritize across and more effectively engage with prescribers. This improved focus and relevance helps the rig prescribers get treatments to patients who could benefit from them.					
IQVIA Orchestrated Analytics	It is a commercial data management and analytics platform designed to address the challenges of effectively launching new brands, maintaining competitiveness of mature brands, and fostering personalized engagement tailored to complex healthcare provider behaviors. It includes applications for data management, commercial planning, field effectiveness, self-serve analytics, reporting, and recommendations. It is available with IQVIA AI Assistant.	2019				
IQVIA AI Assistant	It is an innovative, Al-powered solution that enables customers to interact with IQVIA applications via an accessible, conversational interface. It provides rapid answers complex business questions in moments instead of hours or days, offering timely, powerful insights backed by the trust and precision of IQVIA healthcare-grade Al.					
It is a next-generation digital solution designed to transform how patients engage with support programs across their treatment journey. Patient Experience (PX) appropriate persistent challenges in traditional patient support programs – such as low engagement, poor adherence, and fragmented digital ecosystems – by offering a persistent challenges in traditional patient support programs – such as low engagement, poor adherence, and fragmented digital ecosystems – by offering a persistent challenges in traditional patient support programs – such as low engagement, poor adherence, and fragmented digital ecosystems – by offering a persistent challenges in traditional patient support programs across their treatment journey. Patient Experience (PX) appropriate programs across their treatment journey. Patient Experience (PX) appropriate programs across their treatment journey. Patient Experience (PX) appropriate programs across their treatment journey. Patient Experience (PX) appropriate programs across their treatment journey. Patient Experience (PX) appropriate programs across their treatment journey. Patient Experience (PX) appropriate programs across their treatment journey. Patient Experience (PX) appropriate programs across their treatment journey. Patient Experience (PX) appropriate programs across their treatment journey. Patient Experience (PX) appropriate programs across their treatment journey. Patient Experience (PX) appropriate programs across their treatment journey. Patient Experience (PX) appropriate program across their treatment journey. Patient Experience (PX) appropriate program across their treatment journey. Patient Experience (PX) appropriate program across their treatment journey. Patient Experience (PX) appropriate program across their treatment journey. Patient Experience (PX) appropriate program across their treatment journey. Patient Experience (PX) appropriate program across their treatment journey. Patient Experience (PX) appropriate program across their treatment journey. Patient Experie						



IQVIA profile (page 4 of 6)

Case studies

CASE STUDY 1

Enhanced multi-channel marketing for a large pharma company

Business challenge

The client faced challenges in tailoring multi-channel marketing to effectively engage healthcare professionals. Each clinician had unique preferences for communication methods and channels, making it difficult to identify the most suitable approach for the target audience. This complexity hindered its ability to create a targeted and effective engagement strategy.

Solution

- Applied customized machine learning techniques to dynamically measure HCP responsiveness to promotions using extensive data
- · Utilized sensitivity scores by channel and time to prioritize outreach to specific physicians
- Identified the most effective channels for reaching targeted physicians

Impact

- Identified the optimal target audience, timing, and methods for effective cross-channel promotion
- Optimized channels and investment strategies, increasing revenue by over US\$20 million
- · Achieved this revenue growth at no additional cost within seven months of implementation

CASE STUDY 2

Promoted earlier adoption of second-line therapy by prioritizing outreach for a large pharma company

Business challenge

The client faced the challenge of promoting earlier adoption of a second-line treatment for an autoimmune disease, targeting patients at the highest risk of failing current therapy. It also needed to develop ongoing timed alerts for its sales force to enhance outreach. Additionally, it struggled with a lack of significant product differentiation in the market, making it difficult to stand out and effectively communicate the benefits of its treatment.

Solution

- · Developed a machine learning algorithm to identify patients unlikely to respond effectively to its existing treatment
- Linked identified patients to its HCPs for further assessment
- · Prioritized HCPs into groups to enhance commercialization efforts
- Enabled more effective management of the sales force by targeting priority HCPs

Impact

- Determined that patients with recent evidence of pain and steroid administration were more likely to switch therapies
- Found that older patients and those with a longer history of first-line biologics were less likely to
- Identified that patients linked to providers with a higher prescription share of a specific second-line therapy were more likely to switch
- Enabled the identification of more patients likely to transition to the line of therapy and facilitated planning of outreach efforts around the highest priority HCPs



IQVIA profile (page 5 of 6)

Case studies

CASE STUDY 3

Real-time message-recall monitoring for a top-10 global pharma company

Business challenge

The commercial team needed to gauge HCP recall of key messages for a new oncology launch and benchmark them against competitor communications across multiple countries and over time.

Solution

- . Deployed IQVIA ChannelDynamics Verbatim with an embedded AI Assistant, hosted within the client's environment
- Processed raw, local-language verbatims into the platform and applied generative AI to surface near real-time insights on message recall for both the client and competitor brands
- Enabled multi-country, longitudinal comparisons through a unified dashboard

Impact

- · Deeper, faster understanding of messages linked to positive HCP perception and campaign impact
- · Replaced costly, time-consuming post-marketing research (DFUs and trackers) with an always-on insight engine, supporting timely optimization of launch content and spend

CASE STUDY 4

Generative Al field-engagement assistant for a global midsize pharma company

Business challenge

The client's sales reps and KAMs were overwhelmed by fragmented information and administrative tasks, limiting strategic focus and timely HCP engagement.

Solution

- . Embedded an Al Assistant (part of IQVIA Orchestrated Analytics) directly in the CRM
- · Analyzed historical HCP interactions to recommend personalized messages, channels, and content; optimized call schedules and automated routine admin

Impact

- Achieved 27% reduction in HCP call-preparation and follow-up time
- Enabled 85% user-satisfaction rating for insight quality and usability
- Managed 17% increase in medical-call-quality questions completed by reps, signaling richer, more structured engagements

Measure of capability:

IQVIA profile (page 6 of 6)

Everest Group assessment – Leader

Market impact					V	ision and capabilit	ty	
Market adoption	Portfolio mix	Value delivered	Overall	Vision and strategy	Scope of services offered	Innovation and investments	Delivery footprint	Overall

Strengths

- IQVIA offers a deep bench of commercial assets such as E360 (RWD real world data and insights), Launch Lighthouse (product launch planning), Dynamic HCP Profiling and Targeting, and Integrated Field Alerts. These solutions are tailored to drive HCP engagement, brand activation, and personalized outreach strategies
- Through its Global Market Insights Agentic Architecture, IQVIA is building agentic AI workflows that integrate syndicated datasets (for example, sales, volumes, channel spend, and HCP recall) and forecast models to deliver multi-country, persona-specific insights across commercial functions
- It has a broad delivery footprint across onshore, nearshore, and offshore locations, allowing it to serve enterprises across mid-market, large pharma, and MedTech sectors
- IQVIA has established a robust stream of market-facing publications, including thought leadership pieces, case studies, and blogs, which reflect its deep domain expertise and draw on IQVIA's proprietary data assets and real-world evidence

Limitations

- IQVIA's pricing is perceived to be premium, comparatively higher than peers, suggesting the need to evolve its pricing models to showcase value through output-/outcome-based constructs
- Feedback suggests that project execution can feel fragmented, with clients calling for a more structured engagement model and a single point of accountability to ensure alignment across teams
- While IQVIA's platforms are comprehensive, buyers report challenges in tailoring standard solutions to enterprise-specific needs. IQVIA can create open engagement models that can work with clients in tailoring its solutions to their needs and elevate its status as a strategic partner

Appendix


PEAK Matrix® framework

FAQs



Everest Group PEAK Matrix® is a proprietary framework for assessment of market impact and vision and capability

Everest Group PEAK Matrix





Services PEAK Matrix® evaluation dimensions

Measures impact created in the market captured through three subdimensions

Market adoption


Number of clients, revenue base, YoY growth, and deal value/volume

Portfolio mix

Diversity of client/revenue base across geographies and type of engagements

Value delivered

Value delivered to the client based on customer feedback and transformational impact



Measures ability to deliver services successfully. This is captured through four subdimensions

Vision and strategy

Vision for the client and itself: future roadmap and strategy

Scope of services offered

Depth and breadth of services portfolio across service subsegments/processes

Innovation and investments

Innovation and investment in the enabling areas, e.g., technology IP, industry/domain knowledge, innovative commercial constructs, alliances, M&A, etc.

Delivery footprint

Delivery footprint and global sourcing mix



FAQs

- Q: Does the PEAK Matrix® assessment incorporate any subjective criteria?
- A: Everest Group's PEAK Matrix assessment takes an unbiased and fact-based approach that leverages provider / technology vendor RFIs and Everest Group's proprietary databases containing providers' deals and operational capability information. In addition, we validate/fine-tune these results based on our market experience, buyer interaction, and provider/vendor briefings.
- Q: Is being a Major Contender or Aspirant on the PEAK Matrix, an unfavorable outcome?
- A: No. The PEAK Matrix highlights and positions only the best-in-class providers / technology vendors in a particular space. There are a number of providers from the broader universe that are assessed and do not make it to the PEAK Matrix at all. Therefore, being represented on the PEAK Matrix is itself a favorable recognition.
- Q: What other aspects of the PEAK Matrix assessment are relevant to buyers and providers other than the PEAK Matrix positioning?
- A: A PEAK Matrix positioning is only one aspect of Everest Group's overall assessment. In addition to assigning a Leader, Major Contender, or Aspirant label, Everest Group highlights the distinctive capabilities and unique attributes of all the providers assessed on the PEAK Matrix. The detailed metric-level assessment and associated commentary are helpful for buyers in selecting providers/vendors for their specific requirements. They also help providers/vendors demonstrate their strengths in specific areas.
- Q: What are the incentives for buyers and providers to participate/provide input to PEAK Matrix research?
- A: Enterprise participants receive summary of key findings from the PEAK Matrix assessment For providers
 - The RFI process is a vital way to help us keep current on capabilities; it forms the basis for our database - without participation, it is difficult to effectively match capabilities to buyer inquiries
 - In addition, it helps the provider/vendor organization gain brand visibility through being in included in our research reports

- Q: What is the process for a provider / technology vendor to leverage its PEAK Matrix positioning?
- A: Providers/vendors can use their PEAK Matrix positioning or Star Performer rating in multiple ways including:
 - Issue a press release declaring positioning; see our citation policies
 - Purchase a customized PEAK Matrix profile for circulation with clients, prospects, etc. The package includes the profile as well as quotes from Everest Group analysts, which can be used in PR
 - Use PEAK Matrix badges for branding across communications (e-mail signatures, marketing brochures, credential packs, client presentations, etc.)

The provider must obtain the requisite licensing and distribution rights for the above activities through an agreement with Everest Group; please contact your CD or contact us

- Q: Does the PEAK Matrix evaluation criteria change over a period of time?
- A: PEAK Matrix assessments are designed to serve enterprises' current and future needs. Given the dynamic nature of the global services market and rampant disruption, the assessment criteria are realigned as and when needed to reflect the current market reality and to serve enterprises' future expectations.

Stay connected

Dallas (Headquarters) info@everestgrp.com +1-214-451-3000

Bangalore india@everestgrp.com +91-80-61463500

Delhi india@everestgrp.com +91-124-496-1000 London unitedkingdom@everestgrp.com +44-207-129-1318

Toronto canada@everestgrp.com +1-214-451-3000

With you on the journe

Website everestgrp.com

Blog everestgrp.com/blog

Follow us on









Everest Group is a leading research firm helping business leaders make confident decisions. We guide clients through today's market challenges and strengthen their strategies by applying contextualized problem-solving to their unique situations. This drives maximized operational and financial performance and transformative experiences. Our deep expertise and tenacious research focused on technology, business processes, and engineering through the lenses of talent, sustainability, and sourcing delivers precise and action-oriented guidance. Find further details and in-depth content at **www.everestgrp.com**.

Notice and disclaimers

Important information. Please read this notice carefully and in its entirety. By accessing Everest Group materials, products or services, you agree to Everest Group's Terms of Use.

Everest Group's Terms of Use, available at www.everestgrp.com/terms-of-use, is hereby incorporated by reference as if fully reproduced herein. Parts of the Terms of Use are shown below for convenience only. Please refer to the link above for the full and official version of the Terms of Use.

Everest Group is not registered as an investment adviser or research analyst with the U.S. Securities and Exchange Commission, the Financial Industry Regulation Authority (FINRA), or any state or foreign (non-U.S.) securities regulatory authority. For the avoidance of doubt, Everest Group is not providing any advice concerning securities as defined by the law or any regulatory entity or an analysis of equity securities as defined by the law or any regulatory entity. All properties, assets, materials, products and/or services (including in relation to gen AI) of Everest Group are provided or made available for access on the basis such is for informational purposes only and provided "AS IS" without any warranty of any kind, whether express, implied, or otherwise, including warranties of completeness, accuracy, reliability, noninfringement, adequacy, merchantability or fitness for a particular purpose. All implied warranties are disclaimed to the extent permitted by law. You understand and expressly agree that you assume the entire risk as to your use and any reliance upon such.

Everest Group is not a legal, tax, financial, or investment adviser, and nothing provided by Everest Group is legal, tax, financial, or investment advice. Nothing Everest Group provides is an offer to sell or a solicitation of an offer to purchase any securities or instruments from any entity. Nothing from Everest Group may be used or relied upon in evaluating the merits of any investment. Do not base any investment decisions, in whole or part, on anything provided by Everest Group.

Everest Group materials, products and/or services represent research opinions or viewpoints, not representations or statements of fact. Accessing, using, or receiving a grant of access to Everest Group materials, products and/or services does not constitute any recommendation by Everest Group to (1) take any action or refrain from taking any action or (2) enter into a particular transaction. Nothing from Everest Group will be relied upon or interpreted as a promise or representation as to past, present, or future performance of a business or a market. The information contained in any Everest Group material, product and/or service is as of the date prepared and Everest Group has no duty or obligation to update or revise the information or documentation.

Everest Group collects data and information from sources it, in its sole discretion, considers reliable. Everest Group may have obtained data or information that appears in its materials, products and/or services from the parties mentioned therein, public sources, or third-party sources, including data and information related to financials, estimates, and/or forecasts. Everest Group is not a certified public accounting firm or an accredited auditor and has not audited financials. Everest Group assumes no responsibility for independently verifying such information.

Companies mentioned in Everest Group materials, products and/or services may be customers of Everest Group or have interacted with Everest Group in some other way, including, without limitation, participating in Everest Group research activities.